Majority of anaplastic large-cell lymphomas (ALCLs) are associated with the t(2;5)(p23;q35) translocation, fusing the NPM (nucleophosmin) and ALK (anaplastic lymphoma kinase) genes (NPM-ALK). Recent studies demonstrated that ALK may also be involved in variant translocations, namely, t(1;2)(q25;p23), t(2;3)(p23;q21), t(2;17)(p23;q23) and inv(2)(p23q35), which create the TPM3-ALK, TFG-ALK5, CLTC-ALK, and ATIC-ALK fusion genes, respectively. Although overexpression of NPM-ALK has previously been shown to transform fibroblasts, the transforming potential of variant X-ALK proteins has not been precisely investigated. We stably transfected the cDNAs coding for NPM-ALK, TPM3-ALK, TFG-ALK, CLTC-ALK or ATIC-ALK into nonmalignant NIH3T3 cells. All X-ALK variants are tyrosine phosphorylated and their subcellular distribution was in agreement with that observed in tumors. Moreover, our results show that the in vitro transforming capacity of NIH3T3-transfected cells are in relation to the level of X-ALK fusion proteins excepted for TPM3-ALK for which there is an inverse correlation. The differences between the five X-ALK variants with regard to proliferation rate, colony formation in soft agar, invasion, migration through the endothelial barrier and tumorigenicity seem to be due to differential activation of various signaling pathways such as PI3-kinase/AKT. These findings may have clinical implications in the pathogenesis and prognosis of ALKpositive ALCLs.
Introduction
The oncogenic activation of proteins with tyrosine kinase activity resulting from chromosomal rearrangements are frequently associated with human cancers (Rabbitts, 1994; Sawyers and Denny, 1994) . Anaplastic large-cell lymphoma (ALCL) is associated with a recurrent translocation, the t(2;5)(p23;q35), involving the ALK (anaplastic lymphoma kinase) gene at 2p23 which is fused to the NPM (nucleophosmin) gene at 5q35. The ALK gene encodes a tyrosine kinase receptor belonging to the insulin growth factor receptor superfamily, which is normally expressed in nerve cells (Morris et al., 1994 Pulford et al., 1997) and in human neuroblastomas , but silent in normal lymphoid cells . It is postulated that NPM gene promotes the expression of the ALK catalytic domain present in the chimeric NPM-ALK protein. It has been demonstrated that constitutive ALK activity contributes to the malignant transformation of lymphoid cells (Ma et al., 2000) , that retrovirusmediated gene transfer of NPM-ALK causes lymphoid malignancy in mice (Kuefer et al., 1997) , and that NPM-ALK transgenic mice spontaneously developed T-cell or B-cell lymphomas Miething et al., 2003) . Recently, Stoica et al. have reported that the growth factors pleiotrophin and midkine are ligands for the ALK receptor (Stoica et al., 2001 Bowden et al., 2002; Powers et al., 2002) .
NPM-ALK protein not only typically accumulates in the cytoplasm but also in the the nucleus and nucleolus of lymphoma cells (Morris et al., 1995; Mason et al., 1998) . However, in 15-20% of cases, ALK protein staining is restricted to the cytoplasm of tumor cells and a number of translocations other than the t(2;5) have been described. In these variant translocations, ALK gene at 2p23 is associated with different partners, at 1q25, 3q21, 17q23, Xq11-12 or 2q35 (Table 1) (Hernandez et al., 1999; Lamant et al., 1999; Rosenwald et al., 1999; Colleoni et al., 2000; Touriol et al., 2000; Bridge et al., 2001; Tort et al., 2001) . In the t(1;2), the ALK partner is the TPM3 gene that encodes a nonmuscular tropomyosin . The t(2;3) translocation results in a fusion between the TFG gene that encodes the TRK-fused gene and ALK (Hernandez et al., 1999) . The t(2;17) fuses the last exons of the ALK gene to the CLTC gene at 17q23, encoding the clathrin heavy-chain polypeptide (Touriol et al., 2000; Bridge et al., 2001) , while the inv(2)(p23;q35) results in a fusion between the ATIC gene (also designated as pur H) encoding a bifunctional protein, which carries the penultimate and final enzymatic activities of the purine nucleotide synthesis pathway: 5-aminoimidazole-4-carboxamide ribonucleotideformyltransferase/inosine monophosphate cyclohydrolase (AI-CARFT/IMPCHase) and the ALK gene (Colleoni et al., 2000) . These X-ALK variant fusion proteins have the same intracytoplasmic region of ALK but lack the NPM nuclear localization domain, which accounts for the restricted cytoplasmic distribution of TPM3-ALK, TFG-ALK, CLTC-ALK and ATIC-ALK fusion proteins. These fusion proteins share two common features: (i) the partner genes of ALK are constitutively transcribed in cells carrying these fusion genes and (ii) the various amino-terminal fusion partners are able to mediate dimerization (or oligomerization) of the chimeric protein. It was postulated that, in ALCL associated with these various fusion proteins, the oligomerization of the fusion protein mimics ligand binding, which is responsible for the autophosphorylation and the oncogenic properties of X-ALK variant proteins. There is no evidence that these amino-terminal sequences serve additional functions important for oncogenesis other than promoting homo-oligomerization with resultant kinase activation (Duyster et al., 2001) . The only exception thus far reported are rare cases of ALCL associated with a novel chromosomal abnormality, t(2;22)(p23;q11.2), in which ALK gene is fused to the nonmuscular myosin heavy-chain MYH9 gene (Table 1) (Lamant et al., 2003) .
Interestingly, ALK has been recently implicated in the occurrence of a rare nonlymphoid neoplasm, known as inflammatory myofibroblastic tumor. This tumor is associated with various translocations in which ALK is fused to TPM3, TPM4, CLTC or CARS (encoding the cysteinyl-tRNA synthetase) genes (Table 1) (Lawrence et al., 2000; Bridge et al., 2001; Cools et al., 2002) . Of interest, both ALCL and inflammatory myofibroblastic tumor can show the same TPM3-ALK, TPM4-ALK or CLTC-ALK fusion gene with identical breakpoint sites, suggesting that the same oncogenic sequence can produce different tumor types, depending on the cell type in which the rearrangement occurs Lawrence et al., 2000; Touriol et al., 2000; Bridge et al., 2001) .
The aim of the present study was to investigate the effects of five X-ALK chimeric proteins on cell transformation, proliferation rate in low serum concentration medium, invasive power, colony formation in soft agar, transendothelial cell migration and tumorigenicity in nude mice. For this purpose, we used the nontumorigenic NIH3T3 cells stably transfected with recombinant vectors carrying the full-length NPM-ALK, TPM3-ALK, TFG-ALKs, CLTC-ALK or ATIC-ALK cDNAs. As limited information is available with regard to the effects of X-ALK overexpression and the dose-dependent response, we compared the biological effects of X-ALK chimeric protein on cells expressing high, intermediate and low levels of these proteins.
Results
Expression and subcellular localization of the various X-ALK chimeric proteins in NIH3T3 transfected cells NIH3T3 cells stably transfected by constructs carrying the full-length NPM-ALK, TPM3-ALK, TFG-ALK S , CLTC-ALK or ATIC-ALK cDNAs under the control of the CMV promoter were found to be positive in Western blotting and immunostaining with ALK1 monoclonal antibody. Western blotting analysis performed with cell extracts from the different clones showed bands of the expected size, that is, 80, 85, 96, 104 and 250 kDa in RanBP2, Ran-binding protein 2; CARS, cysteinyl-tRNA synthetase; MYH9, nonmuscular myosin heavy chain 9; ALO17, partner with unknown function. The total number of amino acids, molecular weight and subcellular localization of each ALK fusion proteins are indicated (N, nuclear; nu, nucleolus; C, cytoplasmic; CM, cell membrane associated; C granular, cytoplasmic granular; NM, nuclear membrane). These chimeric proteins were characterized (noted +) in ALCL and/or in IMT (inflammatory myofibroblastic tumors)
The five ALK isoforms differ in NIH3T3 cell-transforming potential F Armstrong et al agreement with the molecular weight of the NPM-ALK, TFG-ALK S , ATIC-ALK, TPM3-ALK and CLTC-ALK fusion proteins, respectively ( Figure 1a ). Immunoprecipitation of the cell lysate with anti-ALK and Western blotting with anti-phosphotyrosine (anti-P-Tyr) antibodies clearly showed that the different proteins produced in transfected cells were constitutively tyrosine phosphorylated (Figure 1b) . In vitro kinase assay was also performed and showed that the ALK domain of each fusion protein possessed tyrosine kinase activity (data not shown).
Using confocal microscopy with ALK1 antibody, we also determined the subcellular localization of the X-ALK recombinant proteins in NIH3T3-transfected cells. In agreement with the staining pattern observed in ALCLs, NIH3T3 cells expressing the NPM-ALK protein showed a cytoplasmic, nuclear and nucleolar staining. In contrast, NIH3T3 cells expressing the other X-ALK fusion proteins (i.e. TPM3-ALK, TFG-ALK S , CLTC-ALK or ATIC-ALK) showed a restricted cytoplasmic staining ( Figure 1c) . As previously reported in CLTC-ALK-positive ALCL, NIH3T3 cells expressing The comparison of the growth curves (in the medium containing 2% FCS) of clones expressing the highest level of each X-variants showed that CLTC-ALK-and TFG-ALK S -overexpressing cells proliferate more rapidly than ATIC-ALK-and NPM-ALK-overexpressing cells (Figures 3a, c, d and e) . The proliferation rate of cells expressing high-level TPM3-ALK protein was very low (Figure 3b ).
To assess the anchorage independence of cell growth, a property usually associated with tumorigenicity, X-ALK-and pCDNA3-transfected NIH3T3 cells were cultured in soft agar and their colony-forming efficiency tested. As expected, parental NIH3T3 cells (data not shown) and the pCDNA3-transfected cells showed no anchorage-independent growth in soft agar (Figure 3 right panels). Interestingly, X-ALK-transfected cells gave rise to colonies in soft agar in a dose-dependent relationship to the level of X-ALK protein ( Figure 3 , right panels). This effect was closely correlated with that observed in adherent cell culture ( Figure 3 , right panels), with increasing levels of ALK, leading to increased colony formation in all variants except for TPM3-ALK, in which the number of colonies decreased with high ALK expression. Indeed, cells expressing high protein level (clone 1) exhibited lower number of colonies than clones expressing intermediate (clone 2) or low (clone 3) levels of protein ( Figure 3b ). An increase of threefold (clones 2 and 3) and fourfold (clones 1 and 2) of the TPM3-ALK level resulted in a decrease in 35 and 90%, respectively, of colonies.
Invasion capacity of X-ALK-expressing NIH3T3 cells
In order to evaluate the invasive potential of these X-ALK-transfected cells (clone 1), we tested their capacity to cross a reconstituted basement-membrane matrix in vitro, using invasion chambers. For each transfectant, after 22 h incubation and crystal violet staining, the number of cells that migrated through the membrane was determined. As shown in Figure 4a , pCDNA3-transfected cells were poorly invasive, while the expression of X-ALK protein was associated with The five ALK isoforms differ in NIH3T3 cell-transforming potential F Armstrong et al migratory and invasive properties. Interestingly, TPM3-ALK-transfected cells displayed higher migratory and invasive capacities than NPM-ALK-, ATIC-ALK-, TFG ALK S -and CLTC-ALK-positive cells, approximately 25-, 17-, 14-, 10-and 8-fold increase, respectively, compared to pCDNA3-transfected cells (Figure 4b ).
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As TPM3-ALK fusion proteins interact with wildtype TPM3 and associate to the cytoskeleton (data not shown), we postulated that TPM3-ALK overexpression could be responsible for the alteration of actin filament polymerization and decrease in cell adhesion, which in turn favor the invasive ability of transfected NIH3T3 cells. This hypothesis was supported by the results shown in Figure 4c since the TPM3-ALK expression level parallels the invasive potential.
To further assess the migration capacity of X-ALK NIH3T3-expressing cells, we used an in vitro transendothelial migration assay (Weber et al., 2001; Lee et al., 2003) . We showed that X-ALK NIH3T3-expressing cells displayed differential in vitro migratory capacities to cross a monolayer of endothelial cells. In particular, TPM3-ALK-transfected cells were proved to be the most invasive as found using the matrigel invasion assay (Figure 4d ).
Tumorigenicity of NIH3T3 cells expressing the highest level of X-ALK in nude mice
To evaluate the in vivo transforming properties of the five X-ALK proteins, transfected cells were grafted subcutaneously in athymic nude mice. NPM-ALK-and TFG-ALK S -expressing cells induced rapidly growing tumors at the site of inoculation within 6 days, whereas tumors originating from cells expressing TPM3-ALK, ATIC-ALK or CLTC-ALK appeared a few days later. Mice grafted with pCDNA3-transfected cells did not develop tumors even after 80 days postgraft. All tumorbearing mice were killed after 12 days postgraft and the tumor volume was determined (Figure 5a ). NPM-ALKand TFG-ALK S -expressing NIH3T3 cells demonstrated higher degree of tumorigenicity than ATIC-ALK-and TPM-ALK-expressing cells (Figure 5a ). Tumors grafted with CLTC-ALK-expressing cells developed small tumors with a volume of only 20% compared to that of NPM-ALK-injected mice. Metastatic spread to other organs was investigated by gross examination, but could not be detected due to the short period of observation. The tumors were not left to develop for a longer period of time because mice developed large tumors and began to die from day 14th after subcutaneous injection of X-ALK-expressing cells. All tumors presented similar morphologic features. They showed high cellularity and consisted of spindle cells, some with atypical nuclei, forming fascicles highly suggestive of a fibrosarcoma. Immunostaining showed that all cells were positive for ALK1 and the staining pattern was comparable to that seen in human ALCL (Figure 5b ).
Signaling pathways involved by the X-ALK proteins As described above, the X-ALK fusion proteins are associated with differential effects on NIH3T3 growth, transformation and invasion. To assess whether these differential effects were related to the involvement of different signaling pathways, we investigated some potentially important downstream ALK-effectors (SRC, STAT3, PI3-kinase/AKT). The most interesting result was observed with TPM3-ALK-transfected cells, which showed higher invasive ability than the other X-ALK-transfected NIH3T3 cells. These results prompted The five ALK isoforms differ in NIH3T3 cell-transforming potential F Armstrong et al us to analyse the PI3-kinase/AKT pathway known to be involved in cell migration. As shown in Figure 6a , the PI3-kinase activity and AKT phosphorylation of the different X-ALK-transfected cells were correlated with their transendothelial migration properties. The phosphorylation status of SRC and STAT3, which are activated by ALK protein, was also analysed (Figure 6b ). No significant difference in SRC phosphorylation was detected in cells transfected with X-ALK or the empty vector (Figure 6b ). In contrast, clear different STAT3 phosphorylation levels were found in X-ALKtransfected cells, the highest level being observed in ATIC-ALK-positive cells compared to the others; pCDNA3-transfected cells were negative for STAT3 activation.
Discussion
The results of the present study show that NPM-ALK, TPM3-ALK, TFG-ALKs, CLTC-ALK and ATIC-ALK fusion proteins previously described in human ALCL can be expressed in NIH3T3-transfected cells. NIH3T3 cells expressing these fusion proteins share a number of common features, but also have different biological properties with regard to the subcellular distribution of X-ALK proteins, their growth characteristics, invasion capacity, ability to cross the endothelial barrier and tumorigenicity in nude mice. As previously reported for all X-ALK variants associated with human ALCLs, we demonstrate that NPM-ALK, TPM3-ALK, TFG-ALK S , CLTC-ALK and ATIC-ALK fusion proteins are tyrosine phosphorylated and kinase functional in NIH3T3-transfected cells (Fujimoto et al., 1996; Mason et al., 1998) . The latter findings are in agreement with previous reports demonstrating that X-ALK fusion protein can form homodimers (or oligomers) using dimerization sites at the N-terminus of ALK fusion protein, a mechanism that mimics ligand binding. This phenomenon is responsible for the activation of the ALK catalytic domain (i.e. autophosphorylation of the tyrosine kinase domain of ALK), which accounts for the oncogenic properties of ALK fusion proteins (Duyster et al., 2001) . In addition, the subcellular distribution of each X-ALK fusion protein in NIH3T3-transfected cells is very similar to that observed in human ALCL, both in culture and in tumors growing in nude mice, and strongly dependent on ALK partners. In NPM-ALKexpressing NIH3T3 cells, the particular cytoplasmic, nuclear and nucleolar staining is due to the formation of dimers between wild-type NPM and the fusion NPM-ALK protein (Mason et al., 1998) . The restricted cytoplasmic staining in cells expressing TPM3-ALK, TFG-ALK S , CLTC-ALK or ATIC-ALK is explained by the absence of nuclear localization signal on the amino-terminal portion of these ALK fusion proteins, which cannot enter the nucleus. In CLTC-ALK-positive NIH3T3 cells, the hybrid protein is involved in the formation of the clathrin coat on the surface of vesicles accounting for the granular cytoplasmic staining (Touriol et al., 2000). The five ALK isoforms differ in NIH3T3 cell-transforming potential F Armstrong et al
The results we observed both in vitro and in vivo with stably transfected NIH3T3 cells confirm for NPM-ALK and ATIC-ALK (Trinei et al., 2000) , and clearly demonstrate for the other X-ALK variants the transforming properties as well as the tumorigenicity of X-ALK-expressing cells in nude mice. Moreover, the biological characteristics, including growth properties and proliferation rates of NIH3T3-transfected cells, are dependent on the level of X-ALK fusion proteins and on the ALK partner. Indeed, the study of NIH3T3 clones expressing increasing amounts of NPM-ALK, TFG-ALK S , CLTC-ALK or ATIC-ALK show a correlation between the level of fusion proteins and the in vitro transforming capacities. Unexpectedly, TPM3-ALK expression induces opposite effects (i.e. low proliferation rate and low number of colonies), suggesting that the high level of this protein might interfere with unknown mechanisms involved in the proliferation of NIH3T3 cells. Overall, we also found an opposite correlation between the proliferation rate and invasive properties using 'Matrigel assay' of CTLC-ALK-, TFG-ALK S -, ATIC-ALK-, NPM-ALK-and TPM3-ALK-expressing cells, but the most striking result was observed in TPM3-ALK-positive cells (see Figure 3 middle panel and Figure 4b ). Despite their low proliferation rate, cells expressing a high level of TPM3-ALK protein were found to be much more invasive in vitro than the other X-ALK-expressing cells, and the invasive properties of TPM3-ALK-positive cells correlate with the level of protein expression. (Figure 4c ) (i.e. the higher the TPM3-ALK level, the more invasive are the cells). Such a difference might be related to: (i) differential expression of adhesion molecules involved in cell motility and invasive abilities (e.g. integrins); (ii) secretion of proteolytic enzymes that could facilitate the migration of TPM3-ALK-positive cells by degrading the matrix component; and (iii) alteration of the actin cytoskeleton that regulates shape and movements of the cells. It is well known that tropomyosin is essential to stabilize actin filaments (Cooper, 2002) and it has been previously demonstrated that malignant transformation is associated with the downmodulation of the tropomyosin isoforms TPM-1, TPM-2 and TPM-3 found in nonmuscle cells (Hendricks and Weintraub, 1981; Cooper et al., 1987) . These actin-binding cytoskeletal proteins are virtually undetectable in transformed cell lines generated by the induced expression of oncogenes such as ras, src, raf, mos, fms, fos or erbB, or by infection with tumor inducing viruses such as SV40, Rous sarcoma virus or adenovirus type 5 (Urbancikova and Grofova, 1982; Cooper et al., 1985; Takenaga et al., 1988; Takenaga and Masuda, 1994; Jooss and Muller, 1995; Prasad et al., 1997) . The same phenomenon might occur in TPM3-ALK protein-expressing cells. In addition, in the latter cells, the formation of TPM3-TPM3-ALK heterodimers could potentially decrease the availability of tropomyosin and its interaction with actin, leading to the decrease in cell adhesion and higher invasive capacity. Such a hypothesis is further supported by the direct correlation between the TPM3-ALK level and the invasive capacity of TPM3-ALK-expressing cells. In addition, although a limited number of downstream ALK effectors (SRC, STAT3, PI3-kinase/AKT) were studied, the distinct behavior of TPM3-ALK expressing may also be related to the predominant activation of the PI3-kinase/AKT pathway that is known to be involved in cell migration (Sotsios and Ward, 2000; West et al., 2002) . Note that we also found that NPM-ALK, TFG-ALK , CLTC-ALK, TPM3-ALK and ATIC-ALK fusion proteins differentially activate STAT 3, the highest STAT3 phosphorylation status being observed in ATIC-ALK-expressing cells, a finding in agreement with the results reported by Zamo et al. (2002) in h293T cells. Differences in STAT3 phosphorylation status could participate in ALK oncogenesis through the upregulation of various genes encoding apoptosis inhibitors (Bcl-x), cell cycle regulators (cyclins D1, D2, c-myc) and inducers of angiogenesis (VEGF) (Calo et al., 2003) . No significance in SRC The five ALK isoforms differ in NIH3T3 cell-transforming potential F Armstrong et al phosphorylation was detectable. Taken together, these results demonstrate that the transforming properties of the five X-ALK chimeras depend on a subtle crosstalk between different signaling pathway. Thus, in contrast to previous reports (Duyster et al., 2001) , the differential effects of X-ALK proteins found in the present study suggest that the ALK amino-terminal partner may play a role in X-ALK-associated oncogenesis other than promoting homo-oligomerization with resultant kinase activation. It might be that the differential effect of the five X-ALK proteins on NIH3T3 growth, transformation and invasion reflect the involvement of different signaling pathways.
In conclusion, our findings demonstrate the transforming properties of X-ALK fusion proteins in both in vitro and in vivo models. The effects of the different X-ALK variants are dependent on the level of X-ALK protein in transfected cells and, except for TPM3-ALKexpressing NIH3T3 cells, the higher the level of X-ALK protein, the more proliferative the cells are. However, no clear correlation was established between in vitro growth characteristics such as proliferation rate and anchorageindependent growth ability and the tumorigenicity in nude mice. The biologic behavior of cells expressing TPM3-ALK protein, different from NIH3T3 cells expressing the other X-ALK variants, suggests that the partner of ALK may serve additional functions for oncogenesis other than promoting homo-oligomerization with resultant kinase activation. In addition, differences between the five X-ALK variants with regard to proliferation rate, colony formation in soft agar, invasion in vitro, migration through the endothelial barrier and tumorigenicity could be due to the activation of the different signaling pathways previously described (Bai et al., 1998; Slupianek et al., 2001; Zamo et al., 2002; Zhang et al., 2002) . Our experimental results are at variance with those previously reported by Falini (2001) and Falini and Mason (2002) , who found no difference in clinical presentation and prognosis fusion proteins between NPM-ALKpositive tumors versus tumors associated with the other X-ALK variants. We are currently collecting large numbers of ALCLs to reassess the clinical implication of these findings.
Materials and methods

Plasmid construction
The constructs pNPM-ALK, pTPM3-ALK, pTFG-ALK S , pCLTC-ALK and pATIC-ALK contained the cDNAs cloned into the pCDNA3 vector, under the control of the cytomegalovirus promoter allowing an efficient transcription of the recombinant cDNA. In pCDNA3 plasmid, the NPM-ALK cDNA was cloned between the HindIII and XbaI sites as described previously (Bischof et al., 1997; Colleoni et al., 2000) . The TPM3-ALK mRNA was amplified by reverse transcriptase-polymerase chain reaction (RT-PCR) with TPM-ATG and ALK-STOP primers (Table 2 ), using total RNA extracted from a lymph node biopsy specimen of a patient with an ALK-positive ALCL bearing the t(1;2) associated with TPM3-ALK hybrid mRNA. The 2.3 kb PCR product was sequenced, digested by HindIII and XbaI and ligated into the HindIII and XbaI sites of the pCDNA3 vector to produce the pTPM3-ALK. The 5 0 portion of TFG-ALK S and ATIC-ALK was amplified by RT-PCR using total RNA prepared from biopsy specimens of patients with TFG-ALK Spositive and ATIC-ALK-positive ALCL with TFG-ATG or ATIC-ATG and ALK2 primers, respectively ( Table 2 ). The RT-PCR products were digested with NcoI and BlpI, and these fragments were used to substitute the corresponding junction fragment of pTPM3-ALK to give pTFG-ALK and pATIC-ALK, respectively. CLTC-ALK was also amplified by RT-PCR using total RNA prepared from a CLTC-ALKpositive tumor. CLTC-ALK cDNA was obtained by PCR using, respectively, the primer couples CLTC-ATG and CLTC-8 (PCR1), CLTC-7 and CLTC-4 (PCR2), CLTC-5 and CLTC-9 (PCR3). The junction fragment of CLTC-ALK was amplified using CLTC-10 and ALK-2 primers (PCR4). PCR products were digested, respectively, by HindIII-EcoRI (PCR1), EcoRI-ClaI (PCR2), ClaI-XhoI (PCR3) and XhoIBlpI (PCR4) and ligated in pTPM3-ALK digested by HindIIIBlpI, leading to the substitution of the TPM portion by the CLTC cDNA.
RNA extraction for RT-PCR
Total RNA was extracted from frozen sections of lymph node and skin biopsy specimens, using the RNeasy Midi Kit (Qiagen, Courtaboeuf, France), following the manufacturer's recommendations. RT was performed using specific primer (Table 2) . PCR was performed as reported previously . The five ALK isoforms differ in NIH3T3 cell-transforming potential F Armstrong et al
Cell culture
The cell line NIH3T3 was obtained from ATCC (CRL 1658). These cells were maintained in culture in Dulbecco's modified Eagle's medium (DMEM) (GIBCO BRL) containing 10% fetal calf serum (FCS) (Myoclone-Invitrogen), 2 mmol/l Lglutamine, 1 mmol/l sodium pyruvate, 100 mg/ml penicillin and 100 mg/ml streptomycin and for selection 1 mg/ml geneticin (G418) at 371C in 5% CO 2 . HBMEC cells was a human bone marrow endothelial cell line immortalized (by high T antigen of SV40 virus) but nontumorigenic (kindly provided by BB Weksler) (Schweitzer et al., 1997) . The flasks were prepared by coating with 0.5% gelatin (in distilled water) for 30 min at 371C. These cells were grown in DMEM (GIBCO BRL, Grand Island, NY, USA), supplemented with 7.5 mg/ml of ECGS (endothelial cell growth supplement) (SIGMA, Steinheim, Germany), 3500 U of heparin, 10% FCS (PAN, D Dutscher, Biotech. Gmbh) and 10 mM HEPES and were maintained at 371C in a humidified atmosphere with 5% CO 2 .
Cell transfection
Stable transfected NIH3T3 clones were obtained by Fugen (Boehringer) transfection with the different pX-ALK vectors (see above) and G418 at 1 mg/ml in DMEM (GIBCO BRL) was added 72 h later. The cultures were maintained for 2 weeks in the presence of G418, and 24 clones from each transfection experiment were picked up and transferred onto 24-well plates before cultivation in larger dishes.
Immunostaining and confocal microscopy analyses
Immunostaining of frozen sections from tumors growing in nude mice after subcutaneous injection of transfected NIH3T3 cells was realized as follows. Cryosections (8 mm), on glass slides coated with silane (Sigma Chemical Co), were fixed in acetone for 10 min and stored at À201C. Before staining, slides were placed in 10 mmol/l Na citrate buffer (pH 6) and heated in a microwave oven at 750 W for cycles of 13 and 11 min. Then, slides were removed and allowed to cool for 30 min at room temperature. Endogenous peroxidase was blocked with 2% hydrogen peroxide in methanol for 30 min. The slides were then rinsed before staining using the streptavidin-biotinperoxidase complex (ABC) method with the StreptABCComplex/HRP Duet (Mouse/Rabbit) kit (Dako). Briefly, slides were incubated with the monoclonal antibody ALK1 (gift from Dr K Pulford, Oxford, UK) for 30 min. They were then washed and incubated with biotinylated goat anti-mouse/antirabbit Ig before being washed and incubated for further 30 min with streptavidin/HRP. The peroxidase reaction was developed using diaminobenzidine tetrahydrochloride (Sigma Chemical co). The slides were then counterstained with hematoxylin.
To better assess the subcellular distribution of the different X-ALK proteins, cells cultured onto glass slides were examined using confocal microscopy. Immunocytochemistry was carried out as previously described using monoclonal ALK1 as primary antibody and Cy3-conjugated antibody against mouse IgG (dilution 1 : 250) as secondary antibody (Sigma). Nuclei were labeled with chromomycin A3 (0.1 mg/ ml). Antibody complexes were visualized using a Zeiss LSM510 confocal microscope with a 63 oil objective lens and operture 1.4.
Western blotting
Cell extracts were sonicated in an extraction buffer (Tris-HCl pH 7.5, 20 mmol/l, EDTA 0.5 mmol/l, EGTA 0.5 mmol/l, 10% glycerol, DTT 0.01 mmol/l, 1 mmol/l pefabloc, 1 mmol/l sodium orthovanadate, 4 mmol/l sodium fluoride, 2 mg/ml pepstatin, 10 mg/ml leupeptin, 2 mg/ml aprotinin and 0.2% SDS). Protein quantification was performed using the Bio-Rad DC Protein Assay (Bio Rad). Samples (20 mg per lane) were separated on 7.5% polyacrylamide gels. After electrophoretic transfer, nitrocellulose membranes were blocked with 3% skimmed milk and incubated with ALK1 and actin monoclonal antibodies or with anti-pSTAT3 (SC-8059 Santa Cruz), or Anti-phospho-Src (Tyr416), clone 9A6 (05-677 Upstate) antibody. Antibody binding was detected with rabbit antimouse immunoglobulins/HRP (DAKO) (diluted 1/5000) using a standard chemiluminescence Western Blot protocol (ECL system, Amersham).
Immunoprecipitation NIH3T3 fibroblasts were washed three times with ice-cold PBS. The cells were scraped from a 100 mm dish into 1 ml of lysis buffer (80 mmol/l Tris-HCl pH 7.5, 200 mmol/l NaCl, 20 mmol/l EDTA, 2% Triton X-100 with 1 mmol/l pefabloc, 1 mmol/l sodium orthovanadate, 4 mmol/l sodium fluoride, 2 mg/ml pepstatin, 10 mg/ml leupeptin and 2 mg/ml aprotinin) and kept at 41C in rotation for 30 min. Lysates were precleared and after centrifugation incubated at 41C for 2 h with ALK1-protein G. After centrifugation, immunocomplexes were washed three times with the lysis buffer and then boiled in sample buffer. After separation on SDS-polyacryamide gel, proteins were transferred onto nitrocellulose membranes, as described above, and membranes were incubated with ALK1, anti-actin and anti-phosphotyrosine (4G10) monoclonal antibodies. Antibody binding was detected with rabbit anti-mouse immunoglobulins/HRP (DAKO) (diluted 1/2500), using a standard chemiluminescence Western Blot protocol (ECL system, Amersham).
For p85 immunoprecipitates, 10 6 NIH3T3 cells were lysed with 500 ml of RIPA buffer (50 mM HEPES, pH 7.4, 10 mM EDTA, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 15 mg/ml benzamidine, 1 mg/ml pepstatin and 1 mg/ml leupeptin). Lysates were clarified by using a 10-min centrifugation at 8000 g at 41C. Lysates were precleared with protein ASepharose (Amersham Pharmacia Biotech) and then incubated overnight with anti-p85 antibodies (0.5 mg/ml). After capture by protein A-Sepharose beads and three washes, one-half of the immunocomplexes were tested for in vitro PI-kinase activity and the other half was analysed by SDS-polyacrylamide gel electrophoresis and immunoblotting with relevant antibodies.
In vitro PI3-kinase assay p85 immunoprecipitates were suspended in PI-kinase activity buffer (0.5 mM EDTA, 100 mM NaCl and 50 mM Tris-HCl, pH 7.4, plus 50 mM ATP and 10 mM MgCl 2 ) and incubated with PtdIns (30 mg)/phosphatidylserine (60 mg) vesicles and 15 mCi of [g-32 P]ATP for 30 min at 371C with shaking, according to Whitman et al. (1988) . Reaction products were separated by TLC, visualized by autoradiography and quantified on a PhosphorImager (Molecular Dynamics).
Anchorage-independent growth assay
A total of 5.10 4 cells were resuspended in DMEM containing 0.33%. Noble agar (Gibco) and cells were seeded onto 6-cm dishes over a 0.5% Noble agar lower coat. The cells were fed every 3 days by overlaying the agar with 2 ml medium. The presence of colonies was scored after 14, 23, 30 and 45 days by
The five ALK isoforms differ in NIH3T3 cell-transforming potential F Armstrong et al MTT staining (Yamaji and Fukuda, 1992) . Each dish was incubated 3 h at 371C with 2 mg MTT and photographed.
Measure of cell proliferation in adherent cultures
Crystal violet staining allows the measurement of cell proliferation without the step of cell trypsinization (Arnaud et al., 1999) . In all, 96-well plates were seeded with 400 cells/ well in complete medium (DMEM plus 10% FCS). The next day, the medium was replaced by DMEM plus 2% FCS which was then changed every 2 days. For the proliferation analysis, cells were fixed with 10% glutaraldehyde for 15 min under agitation, washed extensively with double-distilled water and dried for 1 h at room temperature. After the addition of 100 ml of 0.1% crystal violet (in 200 mmol/l formic acid pH 6.8) to each well, the plates were incubated for 30 min at room temperature under agitation. Cells were then washed with water three times, dried for 1 h at room temperature, 100 ml of 10% acetic acid (diluted in 200 mM formic acid (pH 6.7)) was added and plates were shaken for 15 min. Optical density was read at 550 nm.
In vivo tumorigenicity assay
Stable transfected NIH3T3 cells expressing the highest level of X-ALK variant (named clone no. 1) were trypsinized, washed twice with PBS and resuspended in 500 ml of PBS. A total of 5.10 6 cells of each transfectant were injected subcutaneously into five nude mice that were observed over a period of 12 days for all the X-ALK-injected animals or 80 days for the vector alone injected animals. Mice were killed if they showed clear evidence of growing tumor (except for NIH3T3/pCDNA3-injected mice).
Cell invasion assay
The invasive potential of NIH3T3 cells expressing the highest level of X-ALK chimeric protein (clone 1) or transfected by the vector alone (pCDNA3) was assessed using biocoated Matrigel Invasion Chambers (Becton Dickinson). Each chamber consists of a 8-mm size pore filter coated with a reconstituted cell basement-membrane matrix. About 2 Â 10 5 cells expressing NPM-ALK, TPM3-ALK, ATIC-ALK, TFG-ALK S , CLTC-ALK or transfected by the vector alone (pCDNA3) were seeded onto invasion chambers in six-well plates and cultured for 22 h at 371C. To assess the invasive potential, cells present in the lower wells were stained with crystal violet prior to celldensity evaluation. This technique allows a quantitative evaluation of the invasive potential.
In vitro transendothelial migration assay HBMEC cells (2.5 Â 10 5 )/well were plated onto gelatin coated on FALCON HTS FlouroBlok Inserts (8 mM pore size) (Becton Dickinson, Le Pont de Claix, France). The cell culture inserts were put in 24-well FALCON companion plate (Becton Dickinson, Le Pont de Claix, France) containing HBMEC cell culture medium. Confluent HBMEC monolayers were obtained in 3 days without change of the medium. A total of 1 Â 10 6 NIH3T3-transfected cells were serum starved, resuspended in DMEM and labeled for 1 h with 5 mM of Cell Tracker Green CMFDA (5-chloromethylfluorescein diacetate; Molecular probes). After two washes with PBS, cells were added on the endothelial cells confluent monolayer. Cell migration was thus initiated in triplicate and continued for 24 h. At the end of the incubation period, all compartments of the cell migration system (insert, bottom medium and top medium) were recovered to measure fluorescence at emission and excitation wavelengths for FITC. Data were expressed as the percentage of total NIH3T3-transfected cells that had migrated through the endothelial cells monolayer.
